Cargando…

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia

BACKGROUND: Therapy and outcome for elderly acute myeloid leukemia (AML) patients has not improved for many years. Similarly, there remains a clinical need to improve response rates in advanced myelodysplastic syndrome (MDS) patients treated with hypomethylating agents, and few combination regimens...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tibes, Raoul, Al-Kali, Aref, Oliver, Gavin R, Delman, Devora H, Hansen, Nanna, Bhagavatula, Keerthi, Mohan, Jayaram, Rakhshan, Fariborz, Wood, Thomas, Foran, James M., Mesa, Ruben A., Bogenberger, James M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4615363/ https://www.ncbi.nlm.nih.gov/pubmed/26483188 http://dx.doi.org/10.1186/s13045-015-0211-8

Ejemplares similares

Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia
por: Tibes, Raoul, et al.
Publicado: (2019)

Targeting hedgehog signaling in myelofibrosis and other hematologic malignancies
por: Tibes, Raoul, et al.
Publicado: (2014)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Azacytidine (Vidaza®) in the treatment of myelodysplastic syndromes
por: Raj, Kavita, et al.
Publicado: (2006)

A cat with myelodysplastic syndrome by administration of the methylation inhibitor Azacytidine
por: HISASUE, Masaharu, et al.
Publicado: (2021)

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies
por: Bogenberger, J M, et al.
Publicado: (2014)

The prognostic significance of chromosome 17 abnormalities in patients with myelodysplastic syndrome treated with 5‐azacytidine: Results from the Hellenic 5‐azacytidine registry
por: Diamantopoulos, Panagiotis, et al.
Publicado: (2019)

Glutaminase inhibition in combination with azacytidine in myelodysplastic syndromes: Clinical efficacy and correlative analyses
por: Konopleva, Marina, et al.
Publicado: (2023)

Inhibition of lysyl oxidases synergizes with 5-azacytidine to restore erythropoiesis in myelodysplastic and myeloid malignancies
por: Xu, Qingyu, et al.
Publicado: (2023)

Complications of 5-azacytidine: Three cases of severe ischemic colitis in elderly patients with myelodysplastic syndrome
por: MELCHARDT, THOMAS, et al.
Publicado: (2013)

The augmented expression of the cytidine deaminase gene by 5-azacytidine predicts therapeutic efficacy in myelodysplastic syndromes
por: Murakami, Yuichi, et al.
Publicado: (2019)

Outcomes of allogeneic transplant in patients with DDX41 mutated myelodysplastic syndrome and acute myeloid leukemia
por: Baranwal, Anmol, et al.
Publicado: (2022)

5-Azacytidine restores interleukin 6-increased production in mesenchymal stromal cells from myelodysplastic patients
por: Boada, Matilde, et al.
Publicado: (2021)

Antiretroviral activity of 5-azacytidine during treatment of a HTLV-1 positive myelodysplastic syndrome with autoimmune manifestations
por: Diamantopoulos, Panagiotis T, et al.
Publicado: (2012)

Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid
por: Kuendgen, Andrea, et al.
Publicado: (2011)

Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome
por: Sohlberg, Ebba, et al.
Publicado: (2015)

Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle
por: Wang, Xiaobo, et al.
Publicado: (2023)

Observation and treatment in DDX41-mutated acute myeloid leukemia and myelodysplastic syndrome
por: Al-Kali, Aref, et al.
Publicado: (2023)

Development of an Oral Form of Azacytidine: 2′3′5′Triacetyl-5-Azacytidine
por: Ziemba, Amy, et al.
Publicado: (2011)

Successful 5-azacytidine treatment of myeloid sarcoma and leukemia cutis associated with myelodysplastic syndrome: A case report and literature review
por: Katagiri, Takayuki, et al.
Publicado: (2017)

Azacytidine Treatment for VEXAS Syndrome
por: Raaijmakers, Marc H. G. P., et al.
Publicado: (2021)

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023)

Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine
por: Cabezón, Marta, et al.
Publicado: (2018)

Azacytidine Failure Revisited: an Appraisal Based on Real-Life Data from the MDS Registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS)
por: Kotsianidis, Ioannis, et al.
Publicado: (2019)

Teriflunomide restores 5-azacytidine sensitivity via activation of pyrimidine salvage in 5-azacytidine-resistant leukemia cells
por: Imanishi, Satoshi, et al.
Publicado: (2017)

A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome
por: Almasri, Jehad, et al.
Publicado: (2018)

Relative survival following response to 7+3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes:An analysis of four SWOG studies
por: Othus, Megan, et al.
Publicado: (2018)

Cytogenetic effect of 5-azacytidine in patients with hematological malignancies
por: Tsuda, Jessica Romy, et al.
Publicado: (2011)

CNS Involvement in AML Patient Treated with 5-Azacytidine
por: Vasilatou, Diamantina, et al.
Publicado: (2014)

Suppressing nonsense—a surprising function for 5-azacytidine
por: Shao, Ada, et al.
Publicado: (2014)

Targeting the Sonic Hedgehog-Gli1 Pathway as a Potential New Therapeutic Strategy for Myelodysplastic Syndromes
por: Zou, Jixue, et al.
Publicado: (2015)

A case report of a very late response to 5-azacytidine in a patient with lower risk myelodysplastic syndrome: Time to update treatment guidelines for lower risk patients
por: Spetsieris, Nikolaos, et al.
Publicado: (2018)

Clinical efficacy of azacytidine and venetoclax and prognostic impact of Tim-3 and galectin-9 in acute myeloid leukemia and high-risk myelodysplastic syndromes: A single-center real-life experience
por: Giudice, Valentina, et al.
Publicado: (2022)

Sonic Hedgehog Produced by Bone Marrow-Derived Mesenchymal Stromal Cells Supports Cell Survival in Myelodysplastic Syndrome
por: Zou, Jixue, et al.
Publicado: (2015)

Treatment of Chronic Myelomonocytic Leukemia with 5-Azacytidine: Case Reports
por: Rohon, Peter, et al.
Publicado: (2012)

Effects of 5-Azacytidine on Growth and Hypocrellin Production of Shiraia bambusicola
por: Ma, Yan Jun, et al.
Publicado: (2018)

Azacytidine and Venetoclax in Relapsed and Refractory Patients With Angioimmunoblastic T-cell Lymphoma
por: Laribi, Kamel, et al.
Publicado: (2022)

Priming Leukemia with 5-Azacytidine Enhances CAR T Cell Therapy
por: Xu, Ning, et al.
Publicado: (2021)

Human T Lymphotropic Virus Type 1 protein Tax reduces histone levels
por: Bogenberger, James M, et al.
Publicado: (2008)

Serum ferritin and ECOG performance status predict the response and improve the prognostic value of IPSS or IPSS-R in patients with high-risk myelodysplastic syndromes and oligoblastic acute myeloid leukemia treated with 5-azacytidine: a retrospective analysis of the Hellenic national registry of myelodysplastic and hypoplastic syndromes
por: Papageorgiou, Sotirios G., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_6kdjoopj4ruo4bjo9csb83qs41